SARAH NOEL FINCH
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family HUTCHINSON, KS NPI 1144978271
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family KS NOVARTIS PHARMACEUTICALS CORPORATION All categories
General Payments — all program years on this page
$4,028.15
- Category: General Payments
- Program years: PY2022–2024
- Record count: 228
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,393.05 across 76 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,234.06 | 74 |
| Education | $158.99 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $161.55 | 8 |
| EMD Serono, Inc. | $145.87 | 10 |
| Janssen Biotech, Inc. | $142.13 | 9 |
| PFIZER INC. | $124.61 | 12 |
| Celgene Corporation | $101.24 | 5 |
| Exelixis Inc. | $99.00 | 1 |
| Merck Sharp & Dohme Corporation | $84.82 | 4 |
| SOBI, INC | $72.40 | 3 |
| Gilead Sciences, Inc. | $62.73 | 3 |
| Astellas Pharma US Inc | $49.97 | 3 |
| ABBVIE INC. | $44.45 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $42.70 | 3 |
| Pharmacosmos Therapeutics Inc. | $36.02 | 2 |
| Apellis Pharmaceuticals, Inc. | $28.13 | 1 |
| EISAI INC. | $24.89 | 1 |
| Acerta Pharma LLC | $23.26 | 1 |
| ARRAY BIOPHARMA INC | $22.30 | 1 |
| Daiichi Sankyo Inc. | $20.55 | 1 |
| GlaxoSmithKline, LLC. | $20.34 | 1 |
| Coherus Biosciences Inc. | $18.98 | 1 |
| Genmab U.S., Inc. | $18.93 | 1 |
| Myriad Genetic Laboratories, Inc. | $16.46 | 1 |
| Lilly USA, LLC | $15.95 | 1 |
| SpringWorks Therapeutics, Inc. | $15.77 | 1 |
By program year
Records — PY2024 (76)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.